Westport Pharmaceuticals launches Zephrex-D, a tamper-resistant PSE formulation
ST. LOUIS – Westport Pharmaceuticals on Tuesday launched Zephrex-D, a tamper-resistant pseudoephedrine-based decongestant that now is available in retail stores throughout the St. Louis region and the state of Missouri.
The unique formulation of Zephrex-D provides decongestant relief for consumers while protecting against the illicit manufacture of methamphetamine. “The arrival of Zephrex-D is an integral part of a comprehensive solution to help end meth labs and meth-related crime in our local communities, throughout Missouri and ultimately, across our country," stated Paul Hemings, VP and general manager for Westport.
Because it is a pseudoephedrine-based product, it still will be available behind the pharmacy counter as regulated by the Combat Methamphetamine Epidemic Act of 2005. Some local ordinances require prescriptions to purchase pseudoephedrine products, but Zephrex-D has been exempted from the prescription requirement in several instances, the company reported.
Westport Pharmaceuticals has applied to the federal government for an exemption from the restrictions created by CMEA, the company reported on its website Zephrex-d.com/. "This exemption would enable retailers to place Zephrex-D back in their OTC sections, return direct consumer access to pseudoephedrine, save time and administrative costs for pharmacists, all while helping to reduce methamphetamine-related crime. Consumers win, retailers win and ‘meth cooks’ lose."
Zephrex-D is made using Tarex, Highland Pharmaceuticals’ patented technology that blocks the meth-making process while still providing full congestion relief for patients. "Our technology frustrates the most well-known methods of drug abuse, i.e. crushing for inhalation and injection, and extraction for concentrating for injection," Highland Pharmaceuticals stated in explaining the process. "Highland Pharmaceuticals can deliver both opioid-based analgesics and pseudoephedrine in GRAS formulation, thereby providing a new and unconventional approach to combat the issue of drug abuse."
According to Highland, when pseudoephedrine is delivered in the Tarex format, the standard extraction process is derailed, making the attempt to extract the active ingredient from the tablet unsuccessful. Accordingly, the resulting output cannot be used in subsequent steps to make methamphetamine.
Any retailer inquiries regarding Zephrex-D should be directed to Advantage Consumer Healthcare, Westport’s national sales and marketing partner. Either Greg Bradley or Clark Brown can be reached at 412-706-5440, or via email at www.advantagechc.com.
Pfizer closes deal, sells nutrition business to Nestlé for $11.9 billion
NEW YORK — Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.
Pfizer Nutrition, formerly Wyeth Nutrition, supplies nutritional products that are scientifically designed to help meet the needs of infants and young children, as well as pregnant and lactating mothers. The company’s brands — including infant formulas Promil, Progress and Promise Gold, and maternal supplement Materna — are available across more than 60 countries.
OraSure prepares nationwide TV promotion campaign for in-home HIV test
BETHLEHEM, Pa. — HIV test maker OraSure Technologies has appointed a new executive to head its consumer marketing division as it prepares to launch a nationwide TV campaign on Saturday.
The TV campaign will be timed to coincide with World AIDS Day on Saturday and will air on MTV, A&E, BET, E!, Bravo and Logo, as well as on the NBC reality show "The Voice" on Dec. 17.
OraSure also announced the appointment of Kathleen Weber as SVP and general manager of consumer products, reporting to president and CEO Douglas Michels. Weber previously served as SVP at Pfizer Consumer Healthcare, directing the global Rx-to-OTC switch team and managing products, such as Advil, Neosporin, Bengay, Purell and others.
"We are very excited to have Kathy join OraSure to lead our consumer products business," Michels said. "Kathy brings extensive consumer healthcare experience to her role at OraSure. Her leadership will be instrumental in supporting the successful U.S. launch of our OraQuick In-Home HIV Test and expanding our consumer products business in both the U.S. and international markets."